Sponsored Content

Less Is More in mRNA Therapeutics: Developing Big Ideas at Small Scales

In a November 2022 webinar, Linda Mathiasson (strategic customer lead at Cytiva) discussed the significant promise of messenger ribonucleic acid (mRNA), its role in fighting genetic and infectious diseases, and how its production can be scaled to meet the needs of different applications, ranging from large-scale vaccination to production of individual therapies. The Presentation Thanks to the rapid development of mRNA vaccines for COVID-19, the biopharmaceutical industry has gained momentum toward realizing the technology’s potential. The speed, flexibility, and low-cost…

Grow Your CDMO with Automated Aseptic-Filling Workcells

Contract development and manufacturing organizations (CDMOs) and biopharmaceutical companies are facing shortages in capacity for production of clinical trial material. Even as large-volume commercial biofilling capacity has increased significantly since the beginning of the pandemic, drug developers are forced to use inefficient and risky filling methods that leave them with unmet demand. John Harmer (Cytiva’s strategic initiatives leader for aseptic filling) addressed the need for flexibility and capacity for CDMOs and their clients by introducing two gloveless robotic isolator technology…

Shaken or Stirred: Comparing Rocking-Motion and Impeller Technology in Cell Cultivation

For decades, stirred-tank reactors (STRs) have been the gold standard in cell cultivation, particularly in large-scale processes. However, rocking-motion (RM) technology offers an efficient alternative that can be a better choice for certain applications. In a November 2022 webinar, Tobias Schenk (product manager at Sartorius) discussed the two technologies, highlighting the strengths of each and how they can be used in tandem for optimal results. The Presentation RM bioreactor technology mixes nutrients into cell culture media using a wave motion…

Cell-Expansion Benefits Using Hollow-Fiber Bioreactor Technology

In a November 2022 webinar, Stuart Gibb (scientific strategy lead from Terumo Blood and Cell Technologies) explained the benefits of hollow-fiber bioreactors (HFBRs) for cell therapy. They are suitable for both adherent and suspension-adapted cells. Terumo’s bioreactors are designed to enable flexible feeding and waste-management strategies, which are key features that can facilitate optimal cell growth. The Presentation Gibb presented Terumo’s Quantum Flex HFBR platform, which the company launched in September 2022. Bioreactors for the Quantum Flex platform come in…

IDT Biologika on the importance of oncolytic viruses in CGT development

IDT Biologika is a globally operating biopharmaceutical CDMO that specializes in the Contract Development and Manufacturing of vaccines, cell & gene therapeutics including oncolytic viruses, viral vectors, and other biologics for sterile liquid and lyophilized products. Through the utilization of our innovative technologies, we help our clients to advance their prophylactic and therapeutic products to treat serious diseases that impact human health worldwide. How IDT Biologika can support you with Cell & Gene Therapy inquiries was discussed in the following…

Rapid and Efficient Measurement of Critical Quality Attributes and Parameters Using Octet® Bio-Layer Interferometry (BLI) Systems

Critical quality attributes (CQAs) are defined as a physical, chemical, biological, or microbiological property or characteristics that should be within an appropriate limit, range, or distribution to ensure the desired product quality. These essential measurements include product-specific attributes such as size, charge, and glycosylation patterns as well as process-related impurities including host cell proteins and residual Protein A from chromatographic purification. CQAs must be identified early in the discovery process, reflect the target product profile of the drug candidate, and…

Benefits of Real-Time Analytics to Overcome Common Cell Culture Challenges

This webcast features: Nick Randall, Bioprocessing Product Manager, 908 Devices. Faster development cycles, intensified processes, and automation of process control are key initiatives in biotherapeutics manufacturing. However, offline analytics requiring manual intervention are commonly used to monitor critical and time-sensitive process parameters. We describe a new automated approach for optimal growth and production, leveraging sensitive, on-line (sample-free) monitoring of glucose and lactate with automated feed control, and its impact on growth/viability, lower toxic metabolite, and improved PQA. Key takeaways: Explore…

Host Cell Proteins — Bench to Production Solutions

Enzyme-linked immunosorbent assays (ELISA) are commonly used in analytical chemistry. They can be used in process development for biologic therapies to detect and quantitate host cell protein (HCP) contamination. HCP can cause immunogenic responses in patients and reduce efficacy of these therapies and therefore must be removed to meet regulatory requirements. Some challenges you may run into when utilizing ELISAs are how to prepare your samples, choosing the best generic/commercial ELISA for your needs, and ensuring security of supply for…

Magnetic Agitators Score on Climate Friendliness

A major advantage of magnetically coupled agitators is the hermetic separation of the sterile vessel interior from the agitator motor. As no mechanical seal system is required, the risk of contamination entailed by such a system is avoided. There is no requirement to lubricate the seal and no need for energy-intensive pure steam condensate: a sign of the climate friendliness of magnetic mixing technology! Elimination of steam lubrication reduces CO2 footprint Steam generation requires a lot of energy, usually from…

Improving Scalability of AAV and Lentivirus Production: Tailored Transfection Reagents Enable Large-Scale Manufacturing

Scientific advances have increased the safety and efficacy of recombinant viral-vector technology for cell and gene therapies. In this special report, we will discuss how tailored transfection reagents improve the scalability of AAV and lentivirus production. We will also focus on the challenges of scaling up viral vector production platforms and the importance of selecting the right transfection reagent for this process to increase the titer and quality of viral production to generate more therapeutic doses per run. Fill out…